Cargando…

Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis

INTRODUCTION: Nonalcoholic steatohepatitis (NASH) is largely driven by the dysregulation of liver metabolism and inflammation. Bile acids and their receptor Farnesoid X receptor (FXR) play a critical role in the disease development. Here, we investigated whether INT-767, the newly-identified dual FX...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Ying-Bin, Liu, Xin-Yu, Zhan, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052932/ https://www.ncbi.nlm.nih.gov/pubmed/30038487 http://dx.doi.org/10.2147/DDDT.S170518

Ejemplares similares

INT-767—A Dual Farnesoid-X Receptor (FXR) and Takeda G Protein-Coupled Receptor-5 (TGR5) Agonist Improves Survival in Rats and Attenuates Intestinal Ischemia Reperfusion Injury
por: Canovai, Emilio, et al.
Publicado: (2023)

Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome
por: Gay, Martha D., et al.
Publicado: (2022)

Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis
por: Huang, Peng, et al.
Publicado: (2018)

Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved
por: Yoneda, Masato, et al.
Publicado: (2023)

Hepatocellular cystathionine γ lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor
por: Xu, Wenjing, et al.
Publicado: (2022)

INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis
por: Roth, Jonathan D, et al.
Publicado: (2018)

Fermented ginseng, GBCK25, ameliorates steatosis and inflammation in nonalcoholic steatohepatitis model
por: Choi, Naeun, et al.
Publicado: (2019)

Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis
por: Ganbold, Munkhzul, et al.
Publicado: (2019)

The effect of Farnesoid X receptor agonist tropifexor on liver damage in rats with experimental obstructive jaundice
por: Kilavuz, Huseyin, et al.
Publicado: (2021)

Differential Intrahepatic Phospholipid Zonation in Simple Steatosis and Nonalcoholic Steatohepatitis
por: Wattacheril, Julia, et al.
Publicado: (2013)

Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model
por: Anfuso, Beatrice, et al.
Publicado: (2020)

Treatment with Oxidized Phospholipids Directly Inhibits Nonalcoholic Steatohepatitis and Liver Fibrosis Without Affecting Steatosis
por: Mendel, Itzhak, et al.
Publicado: (2016)

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis
por: LIAN, FAN, et al.
Publicado: (2015)

Bile Acid Nuclear Receptor Farnesoid X Receptor: Therapeutic Target for Nonalcoholic Fatty Liver Disease
por: Kim, Sun-Gi, et al.
Publicado: (2016)

Inhibition of Plasminogen Activator Inhibitor 1 Attenuates Hepatic Steatosis but Does Not Prevent Progressive Nonalcoholic Steatohepatitis in Mice
por: Henkel, Anne S., et al.
Publicado: (2018)

Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice
por: Xiang, Minqi, et al.
Publicado: (2023)

Aquaporin-8 ameliorates hepatic steatosis through farnesoid X receptor in obese mice
por: Xiang, Minqi, et al.
Publicado: (2023)

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis
por: Mazo, Daniel FC, et al.
Publicado: (2013)

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
por: Abenavoli, Ludovico, et al.
Publicado: (2020)

Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis
por: Schramm, Christoph, et al.
Publicado: (2022)

Antibiotic pretreatment attenuates liver ischemia–reperfusion injury by Farnesoid X receptor activation
por: Liu, Hanyi, et al.
Publicado: (2022)

Influence of the Bile Acid Transporter Genes ABCB4, ABCB8, and ABCB11 and the Farnesoid X Receptor on the Response to Ursodeoxycholic Acid in Patients with Nonalcoholic Steatohepatitis
por: Kreimeyer, Henriette, et al.
Publicado: (2023)

Effects of resveratrol, exercises and their combination on Farnesoid X receptor, Liver X receptor and Sirtuin 1 gene expression and apoptosis in the liver of elderly rats with nonalcoholic fatty liver
por: Hajighasem, Amir, et al.
Publicado: (2018)

MicroRNA-155 Deficiency Attenuates Liver Steatosis and Fibrosis without Reducing Inflammation in a Mouse Model of Steatohepatitis
por: Csak, Timea, et al.
Publicado: (2015)

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis [Corrigendum]
Publicado: (2013)

Kaempferol attenuates nonalcoholic steatohepatitis by regulating serum and liver bile acid metabolism
por: Lu, Yifei, et al.
Publicado: (2022)

Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats
por: Ceulemans, Laurens J., et al.
Publicado: (2017)

Myeloid FoxO1 depletion attenuates hepatic inflammation and prevents nonalcoholic steatohepatitis
por: Lee, Sojin, et al.
Publicado: (2022)

Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis
por: Lee, Na Young, et al.
Publicado: (2021)

Sulforaphane Attenuates Nonalcoholic Fatty Liver Disease by Inhibiting Hepatic Steatosis and Apoptosis
por: Li, Jinwang, et al.
Publicado: (2021)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis
por: Petrelli, Fausto, et al.
Publicado: (2022)

Soluble CD14 Levels Reflect Liver Inflammation in Patients with Nonalcoholic Steatohepatitis
por: Ogawa, Yuji, et al.
Publicado: (2013)

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor
por: She, Jianglian, et al.
Publicado: (2022)

Gypenosides ameliorate high-fat diet-induced non-alcoholic steatohepatitis via farnesoid X receptor activation
por: Li, Hongshan, et al.
Publicado: (2022)

Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study
por: Erken, Robin, et al.
Publicado: (2021)

The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Cha, Ji-Young, et al.
Publicado: (2018)

The Role of Farnesoid X Receptor in Accelerated Liver Regeneration in Rats Subjected to ALPPS
por: Daradics, Noemi, et al.
Publicado: (2021)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sbntsc677c8voagdanq1ejj4dn